Clinical trial NCT03817957: Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
Official title: Safety and Efficacy of Postoperative i.v. Iron Substitution With Polyglucoferron Compared to Ferric Carboxymaltose and Oral Iron in Patients With Diagnosed Iron Deficiency Who Develop Anaemia Peri- or Postoperatively (IDA II)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Iron Deficiency Anemia
Keywords: post surgery anemia treatment,
Lead sponsor: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Sponsor class: OTHER
Collaborators: name: University Hospital Frankfurt, Department of Anaesthesiology
name: IRON4U
name: University Hospital Frankfurt Institute for Biostatistics & Mathematical Modelling
First posted: 2019-01-28
Enrollment: 407
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2:2:1 distribution Polyglucoferron, Ferric Carboxymaltose i.v., or oral iron substitution with Ferrous sulfate. After safety assessment of first 35 patients treated with Polyglucoferron or Ferric Carboxymaltose i.v. respectively, Ferric Carboxymaltose arm will be closed.

Remaining patients will be distributed in an 2:1 mode to Polyglucoferron or oral iron
Primary purpose: TREATMENT

Brief summary: Iron deficiency anaemia (IDA) in postoperative patients with confirmed preoperative iron deficiency (ID) in a population with planned major surgery who need fast replenishment of iron as judged by the treating physician will be treated with i.v. iron using Polyglucoferron, Ferric Carboxymaltose or oral iron

Detailed description: In this study, patients with confirmed and documented preoperative non-anaemic iron deficiency (diagnosis up to 28 days before surgery in routine pre-surgery monitoring) who develop anaemia within 12 to 72 hours after start of surgery (with additional confirmation at Baseline) and for whom fast replenishment of iron stores is necessary, will be included and substituted within 24h after Screening Visit/V1. Peri- or postoperative anaemia will be assessed as soon as possible but earliest 12 h after surgery. For short term safety analysis iron in urine will be measured in the first urine after the end of i.v. administration in the first 35 patients who are eligible for analysis in each i.v. treatment group. Only those patients are eligible for whom haematuria and/or proteinuria are excluded using dip stick test. The Ferric Carboxymaltose treatment arm will be closed if a sufficient number of patients is included for safety analysis.The study will then be continued for assessment of co-primary efficacy endpoint: The effectiveness of postoperative i.v. iron substitution with Polyglucoferron compared to conventional oral iron substitution with Ferrous sulfate (treatment 28 - 35 days) to normalize Hb-values or to increase Hb-values by at least 1.5 g/dl until visit 4 will be evaluated as well as patient related outcomes, such as the decreased need for allogenic blood transfusions. In addition, the well-being of the patient will be assumed to improve after treatment using the SF36 questionnaire.

Eligibility criteria: Inclusion Criteria:

* Males or female; aged ≥ 18 years
* Patients after major surgery (e.g., orthopaedic/trauma, vascular, visceral, cardiac surgery) with risk of Hb reduction and/or blood loss who develop anaemia defined as haemoglobin of \<12 g/dL for female and \<13 g/dL for men within 12 to 72 h after start of surgery and with confirmation at Baseline
* Confirmed and documented preoperative iron deficiency defined as S-ferritin \<100 ng/mL without anaemia (Hb ≥12 g/dL for female and ≥13 g/dL for male) within 28 days before surgery
* need for fast iron replenishment as judged by the treating physician
* Written informed consent; willing/able to comply with the protocol

Exclusion Criteria:

* Pregnancy in female patients or breastfeeding women
* Female patients not willing to use a safe method of contraception (PEARL index \<1) for the full study period
* Severe physical inability, e.g., American society of anesthesiologists (ASA) physical status IV or V
* Patients receiving blood transfusion 24 week prior surgery
* Non-iron deficiency anaemia, e.g., known Vitamin B12 or folate deficiency, haemoglobinopathy, or unexplained anaemia
* Anticipated medical need for erythropoiesis-stimulating agents during the main study period
* Patients with hemodynamic instability due to any ongoing bleeding. Absence of ongoing bleeding will be confirmed determined either by decision of two independent physicians or by removal of drainage, whichever occurs earlier in routine care)
* Patients with any contraindication to the investigational products, e.g.,

  1. known sensitivity to iron or an ingredient of the investigational products
  2. Significant history of systemic allergic reactions
  3. Haemachromatosis, thalassemia or TSAT \>50% as indicator of iron overload
  4. Acute or chronic intoxication
  5. Infection (patient on non-prophylactic antibiotics)
  6. Chronic liver disease and/or screening Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) above three times the upper limit of the normal range
* Chronic kidney disease, defined as Glomerular Filtration Rate (GFR) \<30 mL/min
* Active uncontrolled immune-mediated diseases such as rheumatoid arthritis or inflammatory bowel disease
* Primary haematologic disease
* Drug or alcohol abuse according to WHO definition
* Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study
* Current or previous participation in another clinical trial during the last 90 days before screening
* Exclusion criteria related to Ferrous sulfate

  1. according to Summary of product characteristics (SmPC)
  2. hypersensitivity to any ingredient in the formulation
  3. concomitant parenteral iron
  4. haemochromatosis, and other iron overload syndromes
* Exclusion criteria related to Ferric Carboxymaltose:

  1. according to Summary of product characteristics (SmPC)
  2. hypersensitivity to the active substance, to Ferric Carboxymaltose or any of its excipients
  3. known serious hypersensitivity to other parenteral iron products
  4. anaemia not attributed to iron deficiency
  5. evidence of iron overload or disturbances in the utilisation of iron
* Exclusion criteria related to Polyglucoferron

  1. hypersensitivity to any ingredient in the formulation
  2. known serious hypersensitivity to other parenteral iron products
  3. anaemia not attributed to iron deficiency
  4. evidence of iron overload or disturbances in the utilisation of iron

Primary outcomes:
measure: Proportion of patients who achieve normalized Hb-levels or increased Hb of at least 1.5 g/dl
timeFrame: Baseline to approximately 30 days post-baseline (visit 4)
measure: pre post difference of volumen-corrected urine iron levels
timeFrame: urine sampled prior to administration and approximately 1 to 8 hours post-baseline
Secondary outcomes:
measure: Proportion of patients with normalization of Hemoglobin (Hb) at visit 4
timeFrame: 30 days after baseline (Visit 4)
measure: Level of Hb until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Level of Transferrin Saturation (TSAT) until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Level of serum-iron until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Level of serum-transferrin until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Level of serum-ferritin until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Value of serum-phosphate levels at visit 4 (i.v. groups only)
timeFrame: baseline and 30 days after baseline (visit 4)
measure: Overall tolerability and number, incidence, seriousness, severity, relationship of Adverse Events (AE) and serious adverse events (SAE) until 30 days after Investigational medicinal product (IMP) administration
timeFrame: baseline to 30 days after last IMP administration
measure: Level of c-reactive protein on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of ALT on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of AST on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of gamma-glutamyltransferase on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of urea nitrogen on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of serum creatinine on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of white blood cells on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Values of thrombocytes on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Changes in systolic blood pressure on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Changes in body temperature on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Changes in pulse rate on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Changes in diastolic blood pressure on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Assessment of general conditions on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of Skin on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of eyes on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of ears on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of mouth on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of nose on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of throat on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of cardiovascular system on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of respiratory system on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of abdomen on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of gastrointestinal tract on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: clinical assessments of kidneys on each available visit
timeFrame: baseline to 30 days after baseline (visit 4)
measure: AEs related to injection/ infusion site reactions (i.v. treatment arms only) and hypersensitivity reactions
timeFrame: baseline to 30 days after last IMP administration
measure: Number of deaths from any cause until visit 4
timeFrame: baseline to 30 days after baseline (visit 4)
measure: Proportion of units of allogenic red blood cell transfusion from BL until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Proportion of patients with need of allogenic red blood cell transfusion from BL until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: treatment effect on change in Quality of Life (SF36) at visit 4 compared to BL
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Duration of hospital stay (days) until visit 4
timeFrame: Baseline to 30 days after baseline (visit 4)
measure: Level ofl iron in plasma after end of iron administration (for the i.v. groups (safety analysis group) only)
timeFrame: time points directly after administration of intravenous (i.v.) treatment (approximately 15 minutes post-baseline)
measure: Level of iron in plasma after urine sampling (for the i.v. groups (safety analysis group) only)
timeFrame: time points after urine sampling (approximately 1 to 8 hours post-baseline)
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Goethe-University
state: Hessia
Study officials:
affiliation: University Hospital of Goethe-University Frankfurt
name: Patrick Meybohm, MD
role: PRINCIPAL_INVESTIGATOR
References: